THE OCULAR TOLERABILITY OF A NEW OPHTHALMIC DRUG-DELIVERY SYSTEM (NODS)

被引:14
|
作者
DIESTELHORST, M
KRIEGLSTEIN, GK
机构
[1] University Eye Hospital of Cologne, Cologne 41, 5000
关键词
GLAUCOMA; OPHTHALMIC DRUG DELIVERY SYSTEMS; VISUAL ANALOG SCALES;
D O I
10.1007/BF00919405
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
In an open label, two period cross-over study we compared the ocular tolerability of NODS vs. Isopto-Naturale(R) eye drops. Thirty healthy volunteers were asked to rate the application system they were using for ocular discomfort, utilizing a visual analog scale in which 100 = no ocular discomfort and 0 = severe ocular discomfort. In addition each subject had to answer a questionaire and underwent a full ophthalmic control before, at day 7, at day 14 and at day 21 of the study. Each application form had to be applied to one eye only once a day for 7 days, followed by a washout period of 1 week. The type of application form was then changed and again had to be applied to one eye only for 7 consecutive days, followed by a final ophthalmic examination. The mean irritation score was recorded at day 7 and at day 21 of the study. Volunteers had no history of eye disease, no acute pathology of the eye, no contact lenses, no conditional foreign body of the cornea within the last four weeks prior to the study or within the study, no local therapy, no systemic therapy, no diabetes, no pregnancy. Informed consent was obtained. At day 1 one of the two application forms was given to each volunteer in a randomized order. 29 volunteers finished the protocol (16 male, 13 female); mean age: 26 years (range 20-32 years). The mean irritation score of NODS: 35 (2-81); the mean irritation score of Isopto-Naturale(R): 80.4(45.5-99). The difference of mean irritation score (NODS vs. Isopto-Naturale(R)): 46.7 (3.3-82.1) (p < 0.01). The results of the study indicate that in healthy volunteers NODS are not as well tolerated as conventional eye drops when compared for ocular discomfort. However, the chance of applying drugs without preservatives and the possibility of increasing the rate of bioavailability from the new route (NODS) as well as the proportionally reduced risk to the patient of systemic side effects after NODS application of any type of drugs should be taken into consideration.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 50 条
  • [1] OPHTHALMIC PRESERVATIVES AS ABSORPTION PROMOTERS FOR OCULAR DRUG-DELIVERY
    SASAKI, H
    NAGANO, T
    YAMAMURA, K
    NISHIDA, K
    NAKAMURA, J
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (09) : 703 - 707
  • [2] NEW OPHTHALMIC DRUG-DELIVERY SYSTEMS
    LEBOURLAIS, CA
    TREUPELACAR, L
    RHODES, CT
    SADO, PA
    LEVERGE, R
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (01) : 19 - 59
  • [3] THE OPHTHALMIC ROD - A NEW DRUG-DELIVERY SYSTEM .2.
    ALANI, SD
    HAMMERSTEIN, W
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1990, 228 (04) : 302 - 304
  • [4] DRUG-RELEASE FROM AN OPHTHALMIC INSERT OF A BETA-BLOCKER AS AN OCULAR DRUG-DELIVERY SYSTEM
    SASAKI, H
    TEI, C
    NISHIDA, K
    NAKAMURA, J
    JOURNAL OF CONTROLLED RELEASE, 1993, 27 (02) : 127 - 137
  • [5] MICROPARTICULATES FOR OPHTHALMIC DRUG-DELIVERY
    JOSHI, A
    JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (01): : 29 - 45
  • [6] OCULAR DRUG-DELIVERY - PREFACE
    SCHOENWALD, RD
    ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (01) : 1 - 1
  • [7] OCULAR DRUG-DELIVERY CONVENTIONAL OCULAR FORMULATIONS
    LANG, JC
    ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (01) : 39 - 43
  • [8] SCINTIGRAPHIC ASSESSMENT OF THE PRECORNEAL RESIDENCE OF A NEW OPHTHALMIC DELIVERY SYSTEM (NODS) IN MAN
    FITZGERALD, P
    WILSON, CG
    GREAVES, JL
    FRIER, M
    HOLLINGSBEE, D
    GILBERT, D
    RICHARDSON, M
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 83 (1-3) : 177 - 185
  • [9] OPHTHALMIC RODS - NEW OCULAR DRUG DELIVERY DEVICES
    GWON, A
    BORRMANN, LR
    DUZMAN, E
    ROBINS, DS
    SHEN, D
    OPHTHALMOLOGY, 1986, 93 (09) : 82 - 85
  • [10] THE ROLE OF IONTOPHORESIS IN OCULAR DRUG-DELIVERY
    SARRAF, D
    LEE, DA
    JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (01): : 69 - 81